A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

Key facts

Study ID

NCT03114657

Run by

Hoffmann-La Roche

People needed

806

Starts

2017-03-29

Expected to finish

2019-06-11

Last updated by the study team

2020-07-16

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Weight between 40 and 120 kilograms (Kg) inclusive
• Availability of a person (referred to as the "caregiver") who in the investigator's judgment:
• Has frequent and sufficient contact with the participant to be able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits (which require partner input for scale completion), signs the necessary consent form, and has sufficient cognitive capacity to accurately report upon the participant's behavior and cognitive and functional abilities
• Fluency in the language of the tests used at the study site
• Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eye glasses and hearing aids are permitted)
• Evidence of the AD pathological process, by a positive amyloid assessment either on cerebrospinal fluid (CSF) amyloid beta 1-42 levels as measured on the Elecsys beta-amyloid(1-42) test system or amyloid PET scan by qualitative read by the core/central PET laboratory
• Demonstrated abnormal memory function at screening (up to 4 weeks before screening begins) or screening (FCSRT cueing index =<0.67 AND free recall =<27)
• Screening mini mental state examination (MMSE) score of greater than or equal to (>=) 22 points and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 or 1.0
• Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment (MCI)
• If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening
• Participant must have completed at least 6 years of formal education after the age of 5 years

You may not qualify if…

• Any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
• History of major psychiatric illness such as schizophrenia or major depression (if not considered in remission)
• At risk of suicide in the opinion of the investigator
• Any abnormal MRI findings, such as presence of cerebral vascular pathology, cortical stroke, etc or inability to tolerate MRI procedures or contraindication to MRI
• Unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney or liver disease
• Uncontrolled hypertension
• Screening hemoglobin A1c (HbA1C) >8%
• Poor peripheral venous access
• History of cancer except:
• If considered to be cured or If not being actively treated with anti-cancer therapy or radiotherapy
• Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins

Where it is running

• Health Initiatives Research, PLLC — Fayetteville, Arkansas, United States
• Clinical Trials Inc. — Little Rock, Arkansas, United States
• Neuro-Therapeutics Inc. — Pasadena, California, United States
• Desert Valley Medical Group — Rancho Mirage, California, United States
• Anderson Clinical Research, Inc. — Redlands, California, United States
• University of California, Davis; Alzheimers Disease Center, Department of Neurology — Sacramento, California, United States
• UCSF - Memory and Aging Center — San Francisco, California, United States
• MCB Clinical Research Centers — Colorado Springs, Colorado, United States
• Research Center for Clinical Studies, Inc. — Norwalk, Connecticut, United States
• KI Health Partners, LLC; New England Institute for Clinical Research — Stamford, Connecticut, United States
• Georgetown University Hospital — Washington D.C., District of Columbia, United States
• JEM Research LLC — Atlantis, Florida, United States
• Bradenton Research Center — Bradenton, Florida, United States
• Neuropsychiatric Research; Center of Southwest Florida — Fort Myers, Florida, United States
• Alzheimer's Research and Treatment Center — Lake Worth, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Bioclinica Research — Orlando, Florida, United States
• Progressive Medical Research — Port Orange, Florida, United States
• Columbus Memory Center — Columbus, Georgia, United States
• Lake Charles Clinical Trials, LLC — Lake Charles, Louisiana, United States
• Alzheimers Disease Center; Neurology — Winchester, Massachusetts, United States
• Health Partners Institute for Education and Research — Saint Paul, Minnesota, United States
• Precise Research Centers — Flowood, Mississippi, United States
• University of Nebraska Medical Center; Dept of Neurological Sciences — Omaha, Nebraska, United States
• Imaging End Points Clinical Research — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.